GUANGZHOU, China

Xiaqing Wang

This inventor holds 1 USPTO granted patent. Top assignee: Guangzhou Eec Biotech Development Co., Ltd.. Active years: 2024.


% Patents Active = 100.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Xiaqing Wang: Innovator in Chlorin Derivatives and Cancer Treatment

Introduction

Xiaqing Wang is a notable inventor based in Guangzhou, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of chlorin derivatives for cancer treatment. His innovative work focuses on enhancing therapeutic methods through advanced medical systems.

Latest Patents

Xiaqing Wang holds a patent for "Chlorin derivatives or pharmaceutically acceptable salts thereof, preparation method and use thereof, and combination thereof with an ultrasonic medical system." This patent describes a chlorin derivative or a pharmaceutically acceptable salt that can be utilized in photodynamic therapy and sonodynamic therapy. The invention aims to effectively inhibit and treat cancer by combining the chlorin derivative with an ultrasound medical system, which includes a transducer ultrasonic bed and a contact agent.

Career Highlights

Wang is associated with Guangzhou Eec Biotech Development Co., Ltd., where he continues to advance his research and development efforts. His work is pivotal in the ongoing fight against cancer, showcasing his commitment to improving patient outcomes through innovative therapies.

Collaborations

Xiaqing Wang collaborates with talented individuals such as Kun Shao and Qing Li, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Xiaqing Wang's contributions to the field of cancer treatment through his patented chlorin derivatives highlight his role as a leading inventor in pharmaceutical innovation. His work exemplifies the potential of combining advanced materials with medical technology to enhance therapeutic efficacy.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…